Exicure Inc Aktie News
5,32 $
23,43 %
gestern
Nasdaq,
8. Oktober, 22:00 Uhr
tracken
Exicure Inc Aktie News
Neutral
GlobeNewsWire
●
3 Tage alt
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today sh...
Negativ
The Motley Fool
●
2 Monate alt
Exicure Posts Wider Loss in Fiscal Q2
Neutral
Business Wire
●
2 Monate alt
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.
Neutral
Business Wire
●
2 Monate alt
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.
Neutral
Business Wire
●
2 Monate alt
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.
Neutral
Business Wire
●
3 Monate alt
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release.
Neutral
Business Wire
●
4 Monate alt
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.
Neutral
Business Wire
●
5 Monate alt
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
